We are excited to announce that TAE Life Sciences will have a significant presence at the 20th
International Congress on Neutron Capture Therapy (ICNCT), taking place in Krakow, Poland, from June
24 to 28, 2024.
Resources
Recent Blog Posts
Dr. Deepak “Dee” Khuntia Joins TAE Life Sciences’ Board of Directors
We are thrilled to announce the addition of Dr. Deepak “Dee” Khuntia, M.D., FASTRO, to the esteemed Board of Directors at TAE Life Sciences. Dr. Khuntia’s vast expertise in radiation oncology and his significant contributions to advancing cancer treatment technologies significantly reinforce our company’s dedication to pioneering advancements in the field.
Study Published in the Journal of Medicinal Chemistry Shows TAE Life Sciences’ BTS Drug Offers Many Advantages Over BPA for BNCT Use
The team at TAE Life Sciences is thrilled to unveil groundbreaking research that could transform the landscape of cancer care. A recent study, focusing on TAE Life Sciences’ Boronotyrosine (BTS) drug, a novel borylated amino acid analogue, has demonstrated exceptional potential to elevate the effectiveness of BNCT in combating cancer.
White Papers
The Promise of Biologically Targeted Brain Cancer Treatment
How BNCT will improve outcomes for the most difficult-to-treat cancers
Novel Particle Therapy Whitepaper
Dramatic advances in cancer treatment have completely transformed the landscape of cancer care in the last several decades.
Developing targeted drugs for boron neutron capture therapy to treat refractory cancers
TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.
Videos
Have questions about BNCT? Get answers on our new BNCT Forum